Pharsight

1. List of Mounjaro drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9474780	ELI LILLY AND CO	GIP and GLP-1 co-agonist compounds	Jan, 2036 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394	ELI LILLY AND CO	Automatic injection device with delay mechanism including dual functioning biasing member	Feb, 2031 (7 years from now)
US9402957	ELI LILLY AND CO	Automatic injection device with delay mechanism including dual functioning biasing member	Jun, 2031 (8 years from now)
US11357820	ELI LILLY AND CO	GIP/GLP1 agonist compositions	Jun, 2039 (16 years from now)

Do you want to check out MOUNJARO patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 13, 2027

NCE-1 date: 2026-05-13

Market Authorisation Date: 13 May, 2022

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS